- Home
- ATGE vs RYTM Comparison
ATGE vs RYTM Comparison
Compare ATGE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- RYTM
- Stock Information
- Founded
- ATGE 1987
- RYTM 2008
- Country
- ATGE United States
- RYTM United States
- Employees
- ATGE N/A
- RYTM N/A
- Industry
- ATGE Other Consumer Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ATGE Consumer Discretionary
- RYTM Health Care
- Exchange
- ATGE Nasdaq
- RYTM Nasdaq
- Market Cap
- ATGE 2.7B
- RYTM 3.1B
- IPO Year
- ATGE 1991
- RYTM 2017
- Fundamental
- Price
- ATGE $88.82
- RYTM $59.03
- Analyst Decision
- ATGE Buy
- RYTM Strong Buy
- Analyst Count
- ATGE 3
- RYTM 10
- Target Price
- ATGE $85.00
- RYTM $62.30
- AVG Volume (30 Days)
- ATGE 466.2K
- RYTM 701.0K
- Earning Date
- ATGE 10-29-2024
- RYTM 11-05-2024
- Dividend Yield
- ATGE N/A
- RYTM N/A
- EPS Growth
- ATGE 88.45
- RYTM N/A
- EPS
- ATGE 4.36
- RYTM N/A
- Revenue
- ATGE $1,633,207,000.00
- RYTM $112,530,000.00
- Revenue This Year
- ATGE $9.99
- RYTM $63.95
- Revenue Next Year
- ATGE $5.97
- RYTM $43.24
- P/E Ratio
- ATGE $20.31
- RYTM N/A
- Revenue Growth
- ATGE 11.45
- RYTM 81.55
- 52 Week Low
- ATGE $43.78
- RYTM $31.53
- 52 Week High
- ATGE $92.93
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- ATGE 64.35
- RYTM 55.82
- Support Level
- ATGE $86.43
- RYTM $55.37
- Resistance Level
- ATGE $88.64
- RYTM $60.79
- Average True Range (ATR)
- ATGE 3.06
- RYTM 3.60
- MACD
- ATGE -0.11
- RYTM -0.27
- Stochastic Oscillator
- ATGE 71.40
- RYTM 52.59
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.